Clinical and laboratory features predicting a favorable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: A literature review

Journal of Hematotherapy and Stem Cell Research

Volumn 9, Issue 5, 2000, Pages 645-649

  Castagnola, E ^b   Paola, D ^a   Giacchino, R ^b   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; BONE MARROW; CANCER; CANCER CONTROL; CANCER MORTALITY; CLINICAL FEATURE; CONTROLLED STUDY; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; HOSPITAL DISCHARGE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; FEVER; GRANULOCYTES; HUMANS; INFECTION; LENGTH OF STAY; MEDLINE; NEOPLASMS; NEUTROPENIA; PATIENT DISCHARGE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033731128     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160050196687     Document Type: Review

References (35)

1. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
2. European surveillance of infections and risk factors in cancer patients
3. Early discharge of low-risk febrile neutropenic children and adolescents with cancer
4. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia
5. Approach to treatment of the febrile cancer patient with low-risk neutropenia
6. Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia
7. Hematology predictors of bone marrow recovery in patients hospitalized for fever implications for discontinuation of antibiotics and early discharge from the hospital
8. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever
9. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition
10. Short courses of antibiotics in selected febrile neutropenic patients
11. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer
12. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics
13. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complication of sepsis
14. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial
15. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient
16. Outpatient treatment of fever and neutropenia for low-risk pediatric cancer patients
17. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base
18. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer
19. Outpatient treatment of febrile neutropenic patients with cancer
20. Fever and neutropenia in children with malignant disease
21. Outpatient antimicrobial protocol for febrile neutropenia: A nonrandomized prospective trial using ceftriaxone, amikacin and oral adjuvant agents
22. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study
23. Home intravenous antibiotic treatment for febrile episodes in immunecompromised pediatric patients
24. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation
25. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
26. Home antibiotic for low-risk patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule
27. Duration of intravenous antibiotics for patients with neutropenic fever
28. Early hospital discharge of children with fever and neutropenia: A prospective study
29. Evaluation of a home intravenous antibiotic program in pediatric oncology
30. Outpatient parenteral antibiotic therapy for fever and neutropenia
31. Fever and neutropenia. How to use a new treatment strategy
32. Factor associated with bacteremia in febrile granulocytopenic cancer patients
33. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group of EORTC
34. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
35. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk patients with neutropenia during cancer chemotherapy